Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Orchestra BioMed Holdings (OBIO) Treasury Shares (2022 - 2025)

Orchestra BioMed Holdings (OBIO) has disclosed Treasury Shares for 4 consecutive years, with $2.6 million as the latest value for Q3 2025.

  • On a quarterly basis, Treasury Shares rose 11.02% to $2.6 million in Q3 2025 year-over-year; TTM through Sep 2025 was $2.6 million, a 11.02% increase, with the full-year FY2024 number at $2.1 million, up 23.12% from a year prior.
  • Treasury Shares was $2.6 million for Q3 2025 at Orchestra BioMed Holdings, up from $2.2 million in the prior quarter.
  • In the past five years, Treasury Shares ranged from a high of $3.9 million in Q1 2023 to a low of $49237.0 in Q2 2023.
  • A 4-year average of $1.9 million and a median of $2.0 million in 2024 define the central range for Treasury Shares.
  • Biggest YoY gain for Treasury Shares was 4928.3% in 2024; the steepest drop was 56.95% in 2024.
  • Orchestra BioMed Holdings' Treasury Shares stood at $158589.0 in 2022, then surged by 972.72% to $1.7 million in 2023, then increased by 23.12% to $2.1 million in 2024, then increased by 25.42% to $2.6 million in 2025.
  • Per Business Quant, the three most recent readings for OBIO's Treasury Shares are $2.6 million (Q3 2025), $2.2 million (Q2 2025), and $1.9 million (Q1 2025).